(2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-(5-chloro-4-(2-(isopropylsulfonyl)phenylamino)pyrimidin-2-ylamino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-2-oxoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

ID: ALA4476565

PubChem CID: 139293799

Max Phase: Preclinical

Molecular Formula: C57H74ClN9O10S2

Molecular Weight: 1144.86

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(C(=O)COCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](C)c2ccc(-c3scnc3C)cc2)C(C)(C)C)CC1

Standard InChI:  InChI=1S/C57H74ClN9O10S2/c1-33(2)77-47-27-42(35(5)25-45(47)63-56-59-28-43(58)53(65-56)62-44-13-11-12-14-48(44)79(73,74)34(3)4)39-19-21-66(22-20-39)50(70)31-76-24-23-75-30-49(69)64-52(57(8,9)10)55(72)67-29-41(68)26-46(67)54(71)61-36(6)38-15-17-40(18-16-38)51-37(7)60-32-78-51/h11-18,25,27-28,32-34,36,39,41,46,52,68H,19-24,26,29-31H2,1-10H3,(H,61,71)(H,64,69)(H2,59,62,63,65)/t36-,41+,46-,52+/m0/s1

Standard InChI Key:  WIVMQRFHGMKBNK-FFXVWJLRSA-N

Molfile:  

 
     RDKit          2D

 79 85  0  0  0  0  0  0  0  0999 V2000
    3.5618   -4.5523    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.3831   -4.5565    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    3.9781   -3.8426    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.6801   -5.7905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6789   -6.6141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3911   -7.0272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1049   -6.6137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1021   -5.7869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3893   -5.3816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0975   -4.1455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0950   -3.3241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8105   -4.5561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8123   -5.3756    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.5257   -5.7815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5255   -6.6005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2380   -7.0105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9493   -6.5951    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.9435   -5.7695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2304   -5.3674    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.6483   -5.3558    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.3631   -5.7592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3638   -6.5799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0777   -6.9874    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7875   -6.5694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.7789   -5.7439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0644   -5.3443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4863   -5.3277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5026   -6.9749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5076   -7.7972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2189   -8.1996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9296   -7.7884    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.9245   -6.9661    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2087   -6.5551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6393   -8.1935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.8143   -7.0143    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    8.6535   -6.9953    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.6567   -7.8167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9506   -8.2280    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3701   -8.2225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6474   -9.0148    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.3492   -7.7815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0630   -8.1867    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.7728   -7.7747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4866   -8.1798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1965   -7.7678    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.9103   -8.1730    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6201   -7.7609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3298   -8.1661    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.6162   -6.9396    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.3219   -6.5235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3179   -5.7022    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0278   -5.2902    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.6082   -5.2970    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.0357   -6.9328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0396   -7.7541    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7455   -6.5166    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7435   -7.3382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7754   -5.6221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.3232   -5.0109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.9111   -4.3010    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.1088   -4.4736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1361   -5.0944    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   19.4992   -3.9293    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.6658   -3.1293    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.7231   -4.1851    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.1135   -3.6408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.3374   -3.8966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7284   -3.3507    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.9529   -3.6059    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7857   -4.4067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4002   -4.9518    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1733   -4.6938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0131   -4.6654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3494   -4.1887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6909   -4.6727    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.9477   -5.4486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7648   -5.4439    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   18.2801   -2.8408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3448   -3.3716    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  9  2  1  0
  2 10  1  0
 10 11  1  0
 10 12  1  0
  8 13  1  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 14  1  0
 18 20  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 21  1  0
 25 27  1  0
 28 29  1  0
 28 33  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
 32 33  1  0
 24 28  1  0
 31 34  1  0
 15 35  1  0
 22 36  1  0
 36 37  1  0
 37 38  1  0
 37 39  1  0
 34 40  2  0
 34 41  1  0
 41 42  1  0
 42 43  1  0
 43 44  1  0
 44 45  1  0
 45 46  1  0
 46 47  1  0
 47 48  2  0
 47 49  1  0
 50 49  1  6
 50 51  1  0
 51 52  1  0
 51 53  2  0
 50 54  1  0
 54 55  1  0
 54 56  1  0
 54 57  1  0
 52 58  1  0
 58 59  1  0
 59 60  1  0
 60 61  1  0
 61 52  1  0
 59 62  1  1
 61 63  1  6
 63 64  2  0
 63 65  1  0
 65 66  1  0
 66 67  1  0
 67 68  2  0
 68 69  1  0
 69 70  2  0
 70 71  1  0
 71 72  2  0
 72 67  1  0
 73 74  2  0
 74 75  1  0
 75 76  2  0
 76 77  1  0
 77 73  1  0
 70 73  1  0
 66 78  1  6
 74 79  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4476565

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 1144.86

Molecular Weight (Monoisotopic): 1143.4689

AlogP: ┄

#Rotatable Bonds: ┄

Polar Surface Area: ┄

Molecular Species: ┄

HBA: ┄

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): ┄

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: ┄

CX LogD: ┄

Aromatic Rings: ┄

Heavy Atoms: ┄

QED Weighted: ┄

Np Likeness Score: ┄

References

1. Kargbo RB..  (2019)  PROTACs and Targeted Protein Degradation for Treating ALK-Mediated Cancers.,  10  (8): [PMID:31413792] [10.1021/acsmedchemlett.9b00296]

2. Galkin, Anna V AV and 16 more authors.  2007-01-02  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.  [PMID:17185414]

3. McDermott, Ultan U and 24 more authors.  2007-12-11  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.  [PMID:18077425]

4. Sabbatini, Peter P and 19 more authors.  2009-10  GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.  [PMID:19825801]

5. Kim, Mi-hyun MH and 6 more authors.  2011-03-15  Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.  [PMID:21353571]

6. Katayama, Ryohei R and 9 more authors.  2011-05-03  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.  [PMID:21502504]

7. Lovly, Christine M CM and 6 more authors.  2011-07-15  Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.  [PMID:21613408]

8. Kim, Hyangmi; Kim, Minjung; Lee, Junghun; Yu, Hana and Hah, Jung-Mi.  2011-11-15  Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.  [PMID:22014755]

9. Weinberg, Linda R LR and 13 more authors.  2011-12-15  2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.  [PMID:22041060]

10. Tripathy, Rabindranath R and 9 more authors.  2011-12-15  Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.  [PMID:22061645]

11. Song, Zilan Z and 10 more authors.  2015-01-08  Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.  [PMID:24785465]

12. Johnson, Ted W TW and 32 more authors.  2014-06-12  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.  [PMID:24819116]

13. Ott, Gregory R GR and 15 more authors.  2010-12-09  Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.  [PMID:24900237]

14. Michellys, Pierre-Yves PY and 19 more authors.  2016-02-01  Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.  [PMID:26750252]

15. Song, Dawn D and 7 more authors.  2016-04-01  Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.  [PMID:26923695]

16. Zhang, Peilong P and 22 more authors.  2016-04-15  Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.  [PMID:26979157]

17. Huang, Wei-Sheng WS and 33 more authors.  2016-05-26  Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.  [PMID:27144831]

18. Basit, Sulman S, Ashraf, Zaman Z, Lee, Kwangho K and Latif, Muhammad M.  2017-07-07  First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.  [PMID:28431340]

19. Jang, Jaebong J and 10 more authors.  2017-08-18  Discovery of a potent dual ALK and EGFR T790M inhibitor.  [PMID:28528303]

20. Chen, Yongfei Y and 17 more authors.  2017-10-20  Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.  [PMID:28850922]

21. Mah, Shinmee S and 10 more authors.  2017-11-22  Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.  [PMID:29091425]

22. Klaeger, Susan S and 47 more authors.  2017-12-01  The target landscape of clinical kinase drugs.  [PMID:29191878]

23. Gao, Jun-Bo JB and 8 more authors.  2018-04-27  Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.  [PMID:29578342]

24. Zhang, Chengwei C and 6 more authors.  2018-05-10  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).  [PMID:29627725]

25. Powell, Chelsea E CE and 10 more authors.  2018-05-10  Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).  [PMID:29660984]

26. Drilon, Alexander A and 21 more authors.  2018-10  Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.  [PMID:30093503]

27. Luo, Lian-Xiang LX and 9 more authors.  2017-10-01  Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer.  [PMID:30108712]

28. Narayan, Satya S and 7 more authors.  2019-01-01  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.  [PMID:30384048]

29. Watts, Ellen E and 8 more authors.  2019-03-14  Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.  [PMID:30789735]

30. Yan, Guoyi and 11 more authors.  2021-02-11  Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design.  [PMID:33471528]

Source

Source(1):

• Scientific Literature